drugset / Trial / NCT05940532
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
Timeline
- Start
- 2023-06-14
- Primary completion
- 2025-01
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | DDP | Unknown | 75 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Sugemalimab | Monoclonal antibody | 1200 mg | Intravenous |